EP Lab

This channel includes news and new technology innovations for cardiac electrophysiology (EP) systems, techniques and devices using in EP labs. This includes implantable EP devices, pacemakers, implantable cardioverter defibrillators (ICD), cardiac resychronization therapy (CRT), ablation technologies, left atrial appendage (LAA) occlusion, atrial fibrilation (AF) and Holter monitors.

News

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News | EP Lab

May 4, 2022 — CathVision, a medical technology company developing innovative electrophysiology solutions designed to ...

Home May 04, 2022
Home
News | Magnetic Resonance Imaging (MRI)

May 4, 2022 — More than 60 million magnetic resonance imaging (MRI) scans are performed worldwide each year, but imaging ...

Home May 04, 2022
Home
News | Implantable Cardioverter Defibrillator (ICD)

May 2, 2022 – High-risk patients who need defibrillators to prevent cardiac arrest can experience fewer complications ...

Home May 02, 2022
Home
News | EP Lab

April 27, 2022 – CathVision, a medical technology company developing innovative electrophysiology solutions designed to ...

Home April 27, 2022
Home
News | ECG

April 12, 2022 – Biotricity, a medical diagnostic and consumer healthcare technology company, will officially launch the ...

Home April 12, 2022
Home
News | Robotic Systems

April 1, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac ...

Home March 31, 2022
Home
News | Heart Failure

February 25, 2022 – Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved an expanded ...

Home February 25, 2022
Home
News | Catheters
February 9, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, has announced that the company has ...
Home February 09, 2022
Home
By far the two biggest news items from January included the first pig heart transplant into a human patient at the University of Maryland Medical Center, and the FDA clearance of Novarti's inclisiran (Leqvio) twice annual dose injectable LDL lowering drug.
Feature | By Dave Fornell, DAIC Editor

February 1, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) m ...

Home February 01, 2022
Home
The cardiovascular effects of long-hauler COVID in 2022
Feature | Coronavirus (COVID-19) | By Dave Fornell, DAIC Editor

By the end of the first year of the COVID-19 pandemic, there was a clear sign that some virus patients had longer ...

Home January 23, 2022
Home
Subscribe Now